Latest news in cancer
Pembrolizumab and lenvatinib have been approved by the FDA for advanced endometrial cancer
August 2021: Pembrolizumab (Keytruda, Merck) in combination with lenvatinib (Lenvima, Eisai) has been approved by the Food and Drug Administration for patients...
The FDA has approved belumosudil for the treatment of chronic graft-versus-host disease
August 2021: After failure of at least two prior lines of systemic therapy, the Food and Drug Administration approved belumosudil (Rezurock, Kadmon...
Daratumumab and hyaluronidase-fihj plus pomalidomide and dexamethasone have been approved by the FDA for the treatment of multiple myeloma
August 2021: Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) have been approved by the Food and Drug Administration in combination...
The FDA has given enfortumab vedotin-ejfv approval for the treatment of locally advanced or metastatic urothelial carcinoma
August 2021: Enfortumab vedotin-ejfv (Padcev, Astellas Pharma US, Inc.), a Nectin-4-directed antibody and microtubule inhibitor combination, has been approved...
FDA has approved asparaginase erwinia chrysanthemi (recombinant) for leukaemia and lymphoma
August 2021: The Food and Drug Administration has approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as part...
Avapritinib has been approved by the FDA for advanced systemic mastocytosis
August 2021: The FDA approved avapritinib (AyvakitTM, Blueprint Medicines Corp.) for adult patients with advanced systemic mastocytosis (AdvSM), which includes...
Infigratinib receives accelerated approval from the FDA for metastatic cholangiocarcinoma
August 2021: Infigratinib (Truseltiq, QED Therapeutics, Inc.), a kinase inhibitor, has been granted accelerated approval by the Food and Drug Administration...
Sotorasib receives accelerated approval from the FDA for KRAS G12C mutant NSCLC
August 2021: The FDA granted accelerated approval to sotorasib (LumakrasTM, Amgen, Inc.), a RAS GTPase family inhibitor, for adult patients with KRAS G12C...
Amivantamab-vmjw receives fast approval from the FDA for metastatic non-small cell lung cancer
August 2021: The FDA granted amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.), a bispecific antibody directed against epidermal growth factor (EGF) and MET...
Nivolumab has been approved by the FDA for resected esophageal or gastroesophageal junction cancer
August 2021: The FDA has approved Nivolumab (Opdivo, Bristol-Myers Squibb Company) for patients with fully resected oesophagus or gastroesophageal junction...
Pembrolizumab receives accelerated approval from the FDA for HER2-positive gastric cancer
August 2021: Pembrolizumab (Keytruda, Merck & Co.) in combination with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy has been...
The FDA has granted loncastuximab tesirine-lpyl accelerated approval for large B-cell lymphoma
August 2021: The FDA granted loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a CD19-directed antibody and alkylating agent conjugate, accelerated...
Dostarlimab-gxly receives accelerated approval from the FDA for dMMR endometrial cancer
August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) received accelerated approval from the Food and Drug Administration for adult patients with...
Nivolumab in addition to chemotherapy is approved by FDA for metastatic gastric cancer and esophageal adenocarcinoma
August 2021: For advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, the Food and Drug Administration...
Sacituzumab govitecan receives fast approval from the FDA for advanced urothelial cancer
August 2021: Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) was given accelerated approval by the Food and Drug Administration for patients with locally...
Sacituzumab govitecan receives FDA approval for triple-negative breast cancer
August 2021: Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) gained regular FDA clearance for patients with unresectable locally advanced or metastatic...
The FDA has approved idecabtagene vicleucel for the treatment of multiple myeloma
August 2021: The Food and Drug Administration approved idecabtagene vicleucel (Abecma, Bristol Myers Squibb) for the treatment of adult patients with relapsed...
Pembrolizumab has been approved by the FDA for the treatment of esophageal or gastroesophageal junction cancer
August 2021: Pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy has been approved by...
The FDA has approved relugolix for the treatment of advanced prostate cancer
August 2021: The first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix (ORGOVYX, Myovant Sciences, Inc.), was approved by the Food...
Tivozanib has been approved by the FDA for the treatment of relapsed or refractory advanced renal cell carcinoma
August 2021: Tivozanib (Fotivda, AVEO Pharmaceuticals, Inc.), a kinase inhibitor, has been approved by the FDA for adult patients with relapsed or refractory...
Lorlatinib has been approved by the FDA for the treatment of metastatic ALK-positive NSCLC.
August 2021: Lorlatinib (Lorbrena, Pfizer Inc.) received regular FDA approval for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours are...
The FDA has granted axicabtagene ciloleucel expedited approval for relapsed or refractory follicular lymphoma.
August 2021: The FDA has given axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) expedited approval for adult patients with relapsed or refractory...
Lorlatinib has been approved by the FDA for the treatment of metastatic ALK-positive NSCLC
August 2021: Lorlatinib (Lorbrena, Pfizer Inc.) received regular FDA approval for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours are...
Melphalan flufenamide receives approval from the FDA for relapsed or refractory multiple myeloma
August 2021: Melphalan flufenamide (Pepaxto, Oncopeptides AB) in combination with dexamethasone has been granted accelerated approval by the Food and Drug...
Cemiplimab-rwlc has been approved by the FDA for non-small cell lung cancer with high PD-L1 expression
August 2021: The FDA approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) for the first-line treatment of patients with advanced non-small cell...
Cemiplimab-rwlc has been approved by the FDA for the treatment of locally progressed and metastatic basal cell carcinoma
August 20, 2021: The FDA has given cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) regular approval for patients with locally advanced basal cell...
The FDA has approved the first targeted therapy for a lung cancer mutation that was previously thought to be drug-resistant
August 20, 2021: Recently in May, 2021 Lumakras (sotorasib) was approved by the US Food and Drug Administration as the first treatment for adult patients with...
Updated guidelines for food and physical activities for cancer patients
July 2021: The American Cancer Society has modified its cancer preventive diet and physical activity guidelines. A person’s lifetime risk of acquiring or...
Pembrolizumab approved for use in any cancer with a high tumor mutational burden
July 2021: The US Food and Medication Administration (FDA) has expanded the indications for pembrolizumab (Keytruda), an immunotherapy drug, to encompass any...
Liver cancer surgery and transplant by Dr. Selvakumar
July 14, 2021: Check out interview of Dr. Selvakumar Naganathan – Clinical Lead – Liver transplantation and HPB surgery, Apollo Hospitals,...
Atezolizumab plus Bevacizumab for treatment of liver cancer
July 13th 2021: A novel medication for people with a kind of liver cancer called hepatocellular carcinoma is available that appears to be better than standard...
Beta Thalassemia and its consideration with COVID-19
July 2021: Beta-thalassemia is an inherited condition caused by mutations in a gene involved in the production of a component of haemoglobin, the protein that...
Breyanzi – New CAR T-Cell therapy from BMS
July 2021: Breyanzi (Lisocabtagene maraleucel; liso-cel), a novel CD19-directed chimeric antigen receptor (CAR) T cell treatment developed by Bristol Myers...
Easily adoptable methods to improve outcomes in treatment of gastroesophageal cancers
July 9th 2021: During the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2021, two scientists from Roswell Park...
More than 12% of newly diagnosed lung cancer patients newer smoked cigarettes – study suggests
July 7th 2021 : Tobacco smoking is the leading cause of lung cancer, accounting for over 80% of all fatalities from the disease. People who do not smoke,...
Colorectal cancer latest screening guidelines
July 6th 2021 : Colorectal cancer is the among most prevalent cause of cancer death in the the world. Regular screening, on the other hand, can detect...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.